PIA
RARX

Piedmont Investment Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Piedmont Investment Advisors’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-251
Closed -$2K – 2748
2018
Q2 		$2K Buy
+251
New +$1.73K ﹤0.01% 2692

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Piedmont Investment Advisors's RARX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2018, closing a stake of 251 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in RARX in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 69 funds tracked by Wall St. Rank hold RARX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 251 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q2 2018.
  • 69 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.